Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... By Steven Reinberg ... -- Women who are obese during pregnancy may be more ... new review suggests. "We found that, compared with children ... overweight or obese during pregnancy had up to 20 to ... Erick Forno, an assistant professor of pediatrics at Children,s Hospital ...
(Date:7/22/2014)... the University of Utah,s John A. Moran Eye Center, ... Research (ISER) as the recipient of the Houston, Texas-based ... Retina Research., The award recognizes lifetime achievement by a ... the understanding of vitreoretinal diseases or disorders. The award ... Meeting in San Francisco, where Marc will deliver a ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap Manchester ... MD. There has never been a better time in the ... success of the American national soccer team at the 2014 World ... that fans of the world’s sport will be able to feed ... Champions Cup. The tournament will kick off on July 24 and ...
(Date:7/22/2014)... July 22, 2014 (HealthDay News) -- One of the ... a psychiatric disorder has uncovered 83 new sites on ... The findings, made by an international team of researchers, ... linked to the disorder to 108. Although ... as a test to predict who will or will ...
Breaking Medicine News(10 mins):Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... GPRC5A gene, which is under-expressed in human lung cancer cells, ... key to attacking lung cancer in humans, researchers at The ... the Nov. 21 edition of The Journal of the National ... of their GPRC5A genes suppressed developed normally until their second ...
... current laws are too cumbersome , , TUESDAY, Nov. 13 ... in their efforts to protect human research subjects, a ... doctors recently surveyed said that the Health Insurance Portability ... patients, medical information, has hindered research. Only one-quarter felt ...
... Sorting Out the Bitters , Maik Behrens, ... , The story goes that bitter taste receptors ... course, have diverse chemical structures. It has been debated ... whether we need multiple bitter receptors. Bitter taste is ...
... delivery ... technology., CLEVELAND, ... patented, 81 milligram aspirin tablet that,dissolves rapidly in the mouth instead ... of Americans who maintain a,daily aspirin routine and worry about gastrointestinal ...
... Heartburn Alliance Sponsors First Ever Heartburn Awareness Month, ... ... remains a burning problem,for more than 60 million Americans each month(1), ... for heartburn,education by sponsoring the first ever Heartburn Awareness Month. ...
... ... Tennis Champions, CHATHAM, N.J., Nov. 13 The Justin ... Jersey. The event will take place on two dates. On Sunday,December 9, ... tournaments with professional tennis champions. On Thursday,December 13, at 7 PM fans ...
Cached Medicine News:Health News:M. D. Anderson researchers identify tumor-suppressor gene for lung cancer 2Health News:Rules on Patients' Medical Data Hampering Research 2Health News:Rules on Patients' Medical Data Hampering Research 3Health News:News Tips from the Journal of Neuroscience 2Health News:News Tips from the Journal of Neuroscience 3Health News:New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen 2Health News:Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays 2Health News:Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays 3Health News:The Justin Gimelstob Children's Fund Hosts Tennis Exhibition 2
... is an intracorporeal electrokinetic lithotripter particularly ... VIBROLITH guarantees satisfaction in application to ... gall bladder and salivary gland stones. ... percutaneous applications. Kinetic energy transmitted by ...
Combination Ultrasonic and Pneumatic Urological Lithotriptor. Consists of four sizes of rigid pneumatic probes for use in the kidney, ureter and bladder....
... Multiline offers an ideal combination of ... easy and effective treatment of urinary ... wide range of urological applications. ... images enabling rapid, precise stone localization. ...
... MODULITH SLX is not only one of the ... versatile medical workstation. Apart from being designed for ... in the urinary tract, the MODULITH SLX can ... endourological therapies. It is equally suitable for the ...
Medicine Products: